Immunotherapy for pediatric AML
1 Просмотры
• 07/04/23
0
0
встраивать
administrator
Подписчики
Sarah Tasian, MD, Children's Hospital of Philadelphia, Philadelphia, PA, outlines the current immunotherapeutic landscape with a focus on ongoing clinical trials for pediatric patients with acute myeloid leukemia (AML). Specifically, bispecific T-cell-engaging antibodies, natural killer (NK) cells and CAR-T cells are discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Показать больше
Комментарии Facebook
SORT BY-
Лучшие комментарии
-
Последние комментарии